Skip to main content

Table 3 Univariate analysis of clinicopathological factors for OS and DFS in patients with NSCLC (n = 31)

From: CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

Variables

OS

DFS

HR

95%CI

P value

HR

95%CI

P value

Age

  ≤ 55 vs > 55

0.3624

0.1117–1.175

0.0908

0.3255

0.1182–0.8964

0.0299

Gender

 Male vs female

0.7042

0.1642–3.020

0.6368

0.4944

0.1269–1.927

0.3101

Smoking

 Non-smoker vs smoker

1.698

0.4399–6.552

0.4423

1.672

0.5113–5.469

0.395

Histology

 AD vs non-AD

0.9252

0.2659–3.219

0.9027

0.4909

0.1660–1.452

0.1985

Histologic grading

 Poorly

Moderate and well

2.005

0.6213–6.473

0.2445

2.079

0.7724–5.595

0.1474

Venous Invasion

 Negative vs positive

1.352

0.3956–4.619

0.6306

1.237

0.4191–3.653

0.6999

Pathological stage

 I/II vs III

0.3045

0.09458–0.9802

0.0462

0.3044

0.1083–0.8553

0.024

Pre-NAC CMTM1_v17

 Low vs high

0.3753

0.09230-1.526

0.1708

1.002

0.3533–2.842

0.9971

Post-NAC CMTM1_v17

 High vs low

0.1587

0.04462–0.5647

0.0045

0.3099

0.1149–0.8360

0.0207

  1. P value was calculated using a two-sided log-rank test.
  2. AD adenocarcinoma, NAC neoadjuvant chemotherapy, HR hazard ratio (log-rank), CI confidence interval.
  3. Bold values are significant (p < 0.05)
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us